CalciMedica Inc. (CALC)
NASDAQ: CALC
· Real-Time Price · USD
1.76
0.21 (13.55%)
At close: May 02, 2025, 3:59 PM
1.75
-0.57%
After-hours: May 02, 2025, 04:32 PM EDT
13.55% (1D)
| Bid | 1.51 |
| Market Cap | 23.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.7M |
| EPS (ttm) | -1.22 |
| PE Ratio (ttm) | -1.44 |
| Forward PE | -0.88 |
| Analyst | Buy |
| Ask | 1.98 |
| Volume | 40,653 |
| Avg. Volume (20D) | 38,795 |
| Open | 1.53 |
| Previous Close | 1.55 |
| Day's Range | 1.53 - 1.80 |
| 52-Week Range | 1.43 - 6.02 |
| Beta | 1.11 |
About CALC
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC c...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 14, 2023
Employees 14
Stock Exchange NASDAQ
Ticker Symbol CALC
Website https://www.calcimedica.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CALC stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 809.09% from the latest price.
Stock Forecasts1 month ago
-6.17%
CalciMedica shares are trading lower. The company ...
Unlock content with
Pro Subscription
6 months ago
-22.92%
CalciMedica shares are trading lower after the company announced a $10.2 million common stock offering.
